ARG-PRO-PRO-GLY-PHE
ARG-PRO-PRO-GLY-PHE 性质
密度 | 1.46±0.1 g/cm3(Predicted) |
---|---|
储存条件 | -20°C |
溶解度 | 溶于二甲基亚砜 |
酸度系数(pKa) | 3.50±0.10(Predicted) |
形态 | 固体 |
颜色 | 白色至米白色 |
ARG-PRO-PRO-GLY-PHE 用途与合成方法
Bradykinin is a short-lived vasoactive peptide, with a reported half-life in vivo of 17 s, that is rapidly metabolized in the circulation to Bradykinin (1-5). Bradykinin (1-5), the product of two sequential cleavages of Bradykinin by ACE at the Pro7-Phe8 and Phe5-Ser6bonds, has been identified as the major stable metabolite of Bradykinin in vivo in human subjects, with a terminal half-life of minutes. Both Bradykinin and Bradykinin (1-5) inhibit α- and γ-thrombin-induced platelet aggregation (P<0.01 versus baseline). Bradykinin (1-5) inhibits γ-thrombin-induced platelet aggregation 50% at a calculated dose of 183±3 pmol/min. Neither Bradykinin nor Bradykinin (1-5) affects thrombin receptor-activating peptide-induced platelet aggregation, consistent with the hypothesis that Bradykinin and Bradykinin 1-5 inhibit thrombin-induced platelet aggregation by preventing cleavage of the thrombin receptor and liberation of thrombin receptor-activating peptide. Bradykinin (1-5) significantly attenuates α-thrombin-induced platelet aggregation but not TRAP 1-6-induced platelet aggregation. Bradykinin (1-5) potently inhibits γ-thrombin (500 nM)-induced platelet aggregation with an ED 50 of 183±2 pmol/min.
ARG-PRO-PRO-GLY-PHE 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-08-19 | HY-P1488 | ARG-PRO-PRO-GLY-PHE | 23815-89-6 | 1mg | 550 |
2024-08-19 | HY-P1488 | ARG-PRO-PRO-GLY-PHE | 23815-89-6 | 5mg | 1800 |